These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 20890038

  • 1. [Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
    Tanaka Y.
    Clin Calcium; 2010 Oct; 20(10):1545-52. PubMed ID: 20890038
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
    Tanaka Y.
    Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y.
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G.
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [Abstract] [Full Text] [Related]

  • 8. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
    Nakayamada S, Tanaka Y.
    Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Recent progress in the treatment of rheumatoid arthritis].
    Tanaka Y.
    Clin Calcium; 2012 Feb; 22(2):169-78. PubMed ID: 22298069
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
    Fenner H.
    Z Rheumatol; 1995 Feb; 54(3):158-64. PubMed ID: 7660686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
    Herman S, Krönke G, Schett G.
    Trends Mol Med; 2008 Jun; 14(6):245-53. PubMed ID: 18468489
    [Abstract] [Full Text] [Related]

  • 19. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
    Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB.
    Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.